Proprietary AI analyst is now available
- Public Comps
- Cosmo Pharmaceuticals
Cosmo Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cosmo Pharmaceuticals and similar public comparables like Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India and more.
Cosmo Pharmaceuticals Overview
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Founded
1997
HQ

Employees
322
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialCosmo Pharmaceuticals Financials
Cosmo Pharmaceuticals reported last 12-month revenue of $122M and EBITDA of $13M.
In the same LTM period, Cosmo Pharmaceuticals generated $60M in gross profit, $13M in EBITDA, and had net loss of ($2M).
Revenue (LTM)
Cosmo Pharmaceuticals P&L
In the most recent fiscal year, Cosmo Pharmaceuticals reported revenue of - and net income of -.
Financial data powered by Morningstar, Inc.
Cosmo Pharmaceuticals Stock Performance
Cosmo Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Cosmo Pharmaceuticals' stock price is $123.51.
Cosmo Pharmaceuticals share price increased by 70.3% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | - | 16.4% | 70.3% | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCosmo Pharmaceuticals Valuation Multiples
Cosmo Pharmaceuticals trades at 16.2x EV/Revenue multiple, and 153.9x EV/EBITDA.
EV / Revenue (LTM)
Cosmo Pharmaceuticals Financial Valuation Multiples
As of June 7, 2026, Cosmo Pharmaceuticals has market cap of $2B and EV of $2B.
Cosmo Pharmaceuticals has a P/E ratio of (1351.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cosmo Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cosmo Pharmaceuticals Margins & Growth Rates
Cosmo Pharmaceuticals Margins
Cosmo Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Cosmo Pharmaceuticals Operational KPIs
Cosmo Pharmaceuticals' Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cosmo Pharmaceuticals' Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Cosmo Pharmaceuticals Competitors
Cosmo Pharmaceuticals competitors include Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India, BioCryst Pharma, Mineralys Therapeutics, OneSource Specialty, Bavarian Nordic, Duality Biotherapeutics and Ultragenyx.
Most Cosmo Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (13.9x) | (13.5x) | |||
| - | 0.4x | - | 0.7x | |||
| 219.7x | 303.7x | (6.9x) | (6.4x) | |||
| 6.9x | 6.8x | 16.6x | 18.9x | |||
| 3.1x | 3.5x | 7.8x | - | |||
| - | - | (9.0x) | (8.3x) | |||
| 15.4x | 13.9x | 70.8x | 55.7x | |||
| 1.9x | 2.0x | 4.6x | 5.6x | |||
This data is available for Pro users. Sign up to see all Cosmo Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cosmo Pharmaceuticals
| When was Cosmo Pharmaceuticals founded? | Cosmo Pharmaceuticals was founded in 1997. |
| Where is Cosmo Pharmaceuticals headquartered? | Cosmo Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Cosmo Pharmaceuticals have? | As of today, Cosmo Pharmaceuticals has over 322 employees. |
| Who is the CEO of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' CEO is Giovanni Di Napoli. |
| Is Cosmo Pharmaceuticals publicly listed? | Yes, Cosmo Pharmaceuticals is a public company listed on Berlin Stock Exchange. |
| What is the stock symbol of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals trades under C43 ticker. |
| When did Cosmo Pharmaceuticals go public? | Cosmo Pharmaceuticals went public in 2007. |
| Who are competitors of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals main competitors include Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India, BioCryst Pharma, Mineralys Therapeutics, OneSource Specialty, Bavarian Nordic, Duality Biotherapeutics, Ultragenyx. |
| What is the current market cap of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months revenue is $122M. |
| What is the current revenue growth of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Cosmo Pharmaceuticals? | Current revenue multiple of Cosmo Pharmaceuticals is 16.2x. |
| What is the current EBITDA of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months EBITDA is $13M. |
| What is Cosmo Pharmaceuticals' EBITDA margin? | Cosmo Pharmaceuticals' last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Cosmo Pharmaceuticals? | Current EBITDA multiple of Cosmo Pharmaceuticals is 153.9x. |
| What is the current FCF of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months FCF is $8M. |
| What is Cosmo Pharmaceuticals' FCF margin? | Cosmo Pharmaceuticals' last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Cosmo Pharmaceuticals? | Current FCF multiple of Cosmo Pharmaceuticals is 252.9x. |
| How many companies Cosmo Pharmaceuticals has acquired to date? | Cosmo Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Cosmo Pharmaceuticals has invested to date? | Cosmo Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Cosmo Pharmaceuticals
Lists including Cosmo Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.